Please login to the form below
Sir Philip Hampton set to be new GSK chair
RBS chairman to replace Sir Christopher Gent
GlaxoSmithKline (GSK) is set to name the Royal Bank of Scotland's (RBS) Sir Philip Hampton as the company's new chairman, according to local reports.
Several UK media outlets have published stories suggesting GSK will this week officially announce Sir Philip (pictured) as chairman-designate, replacing Sir Christopher Gent when he steps down in 2015.
The news come at a time of pressure for GSK after the company was recently hit with a $487m fine for illegal marketing practices in China.
Sir Philip has served as chairman of the board at RBS since 2009, overseeing the company during a time of global economic collapse.
He has experience in a wide variety of industries, with previous roles including chairman of Sainsbury's and as group finance directory at Lloyds TSB, BT Group, BG Group, British Gas and British Steel.
He is also a former chairman of UK Financial Investments Limited, which manages the UK Government's shareholdings in banks.
Subscribe to our email news alerts
- Planting the Seeds for Future Women Leaders in Medicine
- FDA approves SpringWork’s Ogsiveo as first therapy for desmoid tumours
- GSK shares positive phase 3 results for Blenrep combination in multiple myeloma
- Stem cell therapy trial shows promising results for treating progressive MS
- Cancer Research UK calls on government to create ten-year cancer plan
- Risk calculator to prevent heart attacks and strokes in type 2 diabetes patients
No results were found
PMHub
Kardex
Kardex is a global industry partner for intralogistics solutions and a leading supplier of automated storage solutions and material handling...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
